Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C By Watertime - August 18, 2026 1 Post Content RELATED ARTICLESMORE FROM AUTHOR Weekly Psychedelic Policy Briefing – August 16, 2026 Horizons: Perspectives on Psychedelics Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI
